Sub area of cancer - select from
Name
Contact details
Potential project details/area of research (no more than 50
words)
Medical Oncology
Prof. Laurence Egan
+35391495355
Laurence.egan@nuigalway.ie
Haematological Oncology
Prof Francis J Giles
Tel: +353860448102
Email: frankgiles@aol.com
Haematological Oncology (Multiple
Myeloma)
Dr Sanjeev Gupta
(Supervisor)
Email:Sanjeev.Gupta@nuigalway.ie
Michael.Odwyer@hse.ie
Cancer-immune interactions have profound effects on the
development and spread of tumours. Work we have conducted
in colon cancer patients and in model systems has shown that
specific cytokines of the immune system promote tumour
development and progression. We have also found that
tumours control the immune system in their microenvironment, which in turn regulates tumour growth. This
project will study the molecular factors involved in cancerimmune interactions by adopting a translational approach to
discover novel molecular mechanisms. The project will involve
molecular, epigenomic and bioinformatic techniques.
Fellow would focus on developmental therapeutics in the area
of Jak-2 kinase modulation in myelofibrosis and related
malignancies including development of novel combination
regimens. Fellow would utilise the Phase I/II study conduct and
education resources of the NUIG Clinical Research Facility
including IT, biostatistics, data-management, nursing,
pharmacy, and QA staff.
Role miR-17-92 and miR-106b-25 clusters multiple myeloma
Multiple myeloma (MM) is a clonal B-cell malignancy
characterized by the aberrant expansion of plasma cells (PCs).
microRNA expression profiling has revealed upregulation of
miR-17-92 and the miR-106-25 clusters in MM. We propose to
evaluate the role these microRNA clusters in chemosensitivty
and prognosis in multiple myeloma.
Adverse effects (AE) on urinary, bowel and sexual function may
occur post brachytherapy implantation for prostate cancer. This
project will examine intrinsic phenotypic properties of a
patient’s prostate and inherited genetic polymorphisms that





Surgical Oncology
Medical Oncology
Radiation Oncology
Psycho-Oncology
Haematological Oncology
Prof Michael
O‘Dwyer (cosupervisor)
Radiation Oncology
Prof. Frank Sullivan
Dr. Sharon Glynn
Tel: +353-91-542579
Email: frank.sullivan@hse.ie
Tel: +353-91-494242
Email: sharon.glynn@nuigalway.ie
Medical Oncology
Prof. Frank Giles
Dr. Sharon Glynn
Haematological Oncology
Prof Lokesh Joshi
(supervisor)
Tel: +353-91-495970
Email: francis.j.giles@nuigalway.ie
Tel: +353-91-494242
Email: sharon.glynn@nuigalway.ie
Tel: 091 495768
Email: lokesh.joshi@nuigalway.ie
Prof Michael
O’Dwyer Cosupervisor)
Haematological Oncology
Prof Michael
O’Dwyer (supervisor)
Dept of Haematology, UCHG
Michael.Odwyer@hse.ie
Prof Afshin Samali
(co-supervisor)
Haematological Oncology
Prof Afshin Samali
(supervisor)
Tel: 091 495750
Email: afshin.samali nuigalway.ie
may predispose to the development of AE post brachytherapy
thus facilitating improvements in therapy delivery and efficacy.
Prostate cancer bone metastasis are the greatest barrier to its
cure. This project will develop in vitro/in vivo models of
prostate cancer bone metastasis, in which the interactions
between cancer cells and the bone microenvironment,
particularly the stem cell niche, will be studied and used to test
novel therapeutic agents.
Interactions between multiple myeloma cells and their
microenvironment, mediated by adhesion molecules, such as
integrins and ligands play an important role in dissemination
and drug resistance. This project will look at the effect of
integrin and selectin inhibitors on cell trafficking and drug
resistance in multiple myeloma.
Activation of the IRE1/XBP1 pro-survival branch of the Unfolded
Protein Response promotes the survival of multiple myeloma
cells. Using an IRE1 ribonuclease inhibitor, MKC3946, we plan
to elucidate further the role of this pathway in multiple
myeloma and identify the best partner drugs to use in
combination with IRE1 inhibition.
Overcoming bortizomib resistance in multiple myeloma by
targeting unfolded protein response
Prof Michael
O’Dwyer Cosupervisor)
Haematological Oncology
Prof. Corrado
Santocanale
Tel: +35391495174
Email:
corrado.santocanale@nuigalway.ie
Medical Oncology
Prof. Michael Kerin
Discipline of Surgery, Clinical
Sciences Institute
Cdc7 kinase is a key molecular switch of DNA replication and its
inhibition represents a novel anticancer strategy. By combining
basic and translational research approaches we aim to
understand the relevance of Cdc7 kinase in haematological
malignancies and how Cdc7 inhibitors can be developed into
treatment.
MicroRNAs and Breast Cancer: MiRNAs are short RNA molecules
that regulate gene expression across a range of biological
Tel: (091) 524390
Email: michael.kerin@nuigalway.ie
Medical Oncology
Prof. Terry Smith
(Supervisor)
School of Natural Sciences
Tel. 353 91 495488
Email: terry.smith@nuigalway.ie
Prof. Michael Kerin
(co-supervisors)
Psycho-oncology
Dr. AnnMarie
Groarke
Head, School of Psychology,
NUI, Galway.
Tel: 00353 91 493098
Email:
annmarie.groarke@nuigalway.ie
Psycho-oncology
Dr. Brian McGuire
Psycho-oncology
Dr Jane Walsh
Director, Doctoral Programme in
Clinical Psychology,
Co-Director, Centre for Pain
Research, School of Psychology,
NUI Galway
00353 91) 493266
brian.mcguire@nuigalway.ie
Director , Structured PhD in Health
Psychology,
School of Psychology
NUI Galway
T: +353 91 493102
E: jane.walsh@nuigalway.ie
processes. Recent studies from this laboratory have shown
significantly altered circulating miRNA levels in breast cancer
patients compared with healthy individuals. Cancer-specific
miRNAs in tumour tissue and the circulation will be
investigated.
Correlation of molecular subtypes of breast cancer with
circulating miRNAs suggests there may be specific circulating
miRNA signatures of breast cancer that can be used for early
diagnosis and therapeutic intervention. Our goal is to develop
Point of Care molecular diagnostics assays for the detection of
miRNA signatures to diagnose, subtype and support treatment
of breast cancer and other types of cancer.
The role of illness beliefs and coping strategies on adjustment in
cancer. The efficacy of psychosocial interventions for women
with breast cancer. The influence of psychological predictors on
quality of life in men with prostate cancer. Other interests
include risk perceptions and attitudes to cancer, posttraumatic
growth and benefit finding in the cancer experience,
adjustment strategies in children of mothers with cancer.
Pain management and pain coping in cancer, psychological
impact of cancer, effectiveness of psychological treatments in
cancer, psychological factors affecting disease progression and
recovery, psychological factors affecting outcome of cancer
treatments.
Areas of research interest include: developing strategies to
improve cancer screening and cancer prevention; development
of interventions to reduce anxiety and pain in patients
undergoing cancer treatment. The development of educational
interventions to improve patient adherence to medical advice.